Transcranial magnetic stimulation (TMS) for geriatric depression
The prevalence of treatment-resistant geriatric depression (GD) highlights the need for treatments that preserve cognitive functions and recognize polypharmacy in elderly, yet effectively reduce symptom burden. Transcranial magnetic stimulation (TMS) is a proven intervention for treatment-resistant...
Gespeichert in:
Veröffentlicht in: | Ageing research reviews 2022-02, Vol.74, p.101531-101531, Article 101531 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 101531 |
---|---|
container_issue | |
container_start_page | 101531 |
container_title | Ageing research reviews |
container_volume | 74 |
creator | Cappon, Davide den Boer, Tim Jordan, Caleb Yu, Wanting Metzger, Eran Pascual-Leone, Alvaro |
description | The prevalence of treatment-resistant geriatric depression (GD) highlights the need for treatments that preserve cognitive functions and recognize polypharmacy in elderly, yet effectively reduce symptom burden. Transcranial magnetic stimulation (TMS) is a proven intervention for treatment-resistant depression in younger adults but the efficacy of TMS to treat depressed older adults is still unclear. This review provides an updated view on the efficacy of TMS treatment for GD, discusses methodological differences between trials in TMS application, and explores avenues for optimization of TMS treatment in the context of the ageing brain.
A systematic review was conducted to identify published literature on the antidepressant efficacy of TMS for GD. Databases PubMed, Embase, and PsycINFO were searched for English language articles in peer-reviewed journals in March 2021.
Seven randomized controlled trials (RCTs) (total n = 260, active n = 148, control n = 112) and seven uncontrolled trials (total n = 160) were included. Overall, we found substantial variability in the clinical response, ranging from 6.7% to 54.3%.
The reviewed literature highlights large heterogeneity among studies both in terms of the employed TMS dosage and the observed clinical efficacy. This highlights the need for optimizing TMS dosage by recognizing the unique clinical features of GD. We showcase a set of novel approaches for the optimization of the TMS protocol for depression and discuss the possibility for a standardized TMS protocol tailored for the treatment of GD.
•TMS is a safe nonpharmacological intervention for geriatric depression.•TMS parameters adopted between different trials varied significantly.•TMS clinical efficacy for geriatric depression is highly variable between different trials.•Most of the reviewed studies significantly underdosed TMS for geriatric depression.•It is necessary to optimize TMS treatment by considering the changes of brain as we age. |
doi_str_mv | 10.1016/j.arr.2021.101531 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8996329</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1568163721002786</els_id><sourcerecordid>2604456783</sourcerecordid><originalsourceid>FETCH-LOGICAL-c451t-107f34af2fc9979e0c7b65199a18dc498ff70290095807482d5f1db9fab3b9213</originalsourceid><addsrcrecordid>eNp9kMtOGzEUhi1E1VDoA7CpZgmLCb6Nx0eVUKuotEhULAhry-M5Th3NJbUnSLw9jhJQu2HjY-u_-Ogj5JzROaNMXa3nNsY5p5zt3pVgR-SE6ZqXoCQc53uldMmUqGfkU0prmjOg-EcyE1ILoFKckG_LaIfk8hFsV_R2NeAUXJGm0G87O4VxKC6Wvx8uCz_GYoUx2ClmvcVNxJSyfEY-eNsl_HyYp-Tx5sdy8au8u_95u_h-VzpZsalktPZCWs-9A6gBqasbVTEAy3TrJGjva8qBUqg0raXmbeVZ24C3jWiAM3FKrve9m23TY-twmKLtzCaG3sZnM9pg_leG8MesxiejAZTgkAsuDgVx_LvFNJk-JIddZwcct8lwRaWsVK1FtrK91cUxpYj-7RtGzY68WZtM3uzImz35nPny735viVfU2fB1b8BM6SlgNMkFHBy2IaKbTDuGd-pfABTDlDQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2604456783</pqid></control><display><type>article</type><title>Transcranial magnetic stimulation (TMS) for geriatric depression</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Cappon, Davide ; den Boer, Tim ; Jordan, Caleb ; Yu, Wanting ; Metzger, Eran ; Pascual-Leone, Alvaro</creator><creatorcontrib>Cappon, Davide ; den Boer, Tim ; Jordan, Caleb ; Yu, Wanting ; Metzger, Eran ; Pascual-Leone, Alvaro</creatorcontrib><description>The prevalence of treatment-resistant geriatric depression (GD) highlights the need for treatments that preserve cognitive functions and recognize polypharmacy in elderly, yet effectively reduce symptom burden. Transcranial magnetic stimulation (TMS) is a proven intervention for treatment-resistant depression in younger adults but the efficacy of TMS to treat depressed older adults is still unclear. This review provides an updated view on the efficacy of TMS treatment for GD, discusses methodological differences between trials in TMS application, and explores avenues for optimization of TMS treatment in the context of the ageing brain.
A systematic review was conducted to identify published literature on the antidepressant efficacy of TMS for GD. Databases PubMed, Embase, and PsycINFO were searched for English language articles in peer-reviewed journals in March 2021.
Seven randomized controlled trials (RCTs) (total n = 260, active n = 148, control n = 112) and seven uncontrolled trials (total n = 160) were included. Overall, we found substantial variability in the clinical response, ranging from 6.7% to 54.3%.
The reviewed literature highlights large heterogeneity among studies both in terms of the employed TMS dosage and the observed clinical efficacy. This highlights the need for optimizing TMS dosage by recognizing the unique clinical features of GD. We showcase a set of novel approaches for the optimization of the TMS protocol for depression and discuss the possibility for a standardized TMS protocol tailored for the treatment of GD.
•TMS is a safe nonpharmacological intervention for geriatric depression.•TMS parameters adopted between different trials varied significantly.•TMS clinical efficacy for geriatric depression is highly variable between different trials.•Most of the reviewed studies significantly underdosed TMS for geriatric depression.•It is necessary to optimize TMS treatment by considering the changes of brain as we age.</description><identifier>ISSN: 1568-1637</identifier><identifier>EISSN: 1872-9649</identifier><identifier>DOI: 10.1016/j.arr.2021.101531</identifier><identifier>PMID: 34839043</identifier><language>eng</language><publisher>England: Elsevier B.V</publisher><subject>Aged ; Aging ; Depression - therapy ; Geriatric depression (GD) ; Humans ; Non-invasive brain stimulation ; Nonpharmacological intervention ; Polypharmacy ; Transcranial Magnetic Stimulation ; Transcranial magnetic stimulation (TMS) ; Treatment Outcome</subject><ispartof>Ageing research reviews, 2022-02, Vol.74, p.101531-101531, Article 101531</ispartof><rights>2021</rights><rights>Copyright © 2021. Published by Elsevier B.V.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c451t-107f34af2fc9979e0c7b65199a18dc498ff70290095807482d5f1db9fab3b9213</citedby><cites>FETCH-LOGICAL-c451t-107f34af2fc9979e0c7b65199a18dc498ff70290095807482d5f1db9fab3b9213</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.arr.2021.101531$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34839043$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cappon, Davide</creatorcontrib><creatorcontrib>den Boer, Tim</creatorcontrib><creatorcontrib>Jordan, Caleb</creatorcontrib><creatorcontrib>Yu, Wanting</creatorcontrib><creatorcontrib>Metzger, Eran</creatorcontrib><creatorcontrib>Pascual-Leone, Alvaro</creatorcontrib><title>Transcranial magnetic stimulation (TMS) for geriatric depression</title><title>Ageing research reviews</title><addtitle>Ageing Res Rev</addtitle><description>The prevalence of treatment-resistant geriatric depression (GD) highlights the need for treatments that preserve cognitive functions and recognize polypharmacy in elderly, yet effectively reduce symptom burden. Transcranial magnetic stimulation (TMS) is a proven intervention for treatment-resistant depression in younger adults but the efficacy of TMS to treat depressed older adults is still unclear. This review provides an updated view on the efficacy of TMS treatment for GD, discusses methodological differences between trials in TMS application, and explores avenues for optimization of TMS treatment in the context of the ageing brain.
A systematic review was conducted to identify published literature on the antidepressant efficacy of TMS for GD. Databases PubMed, Embase, and PsycINFO were searched for English language articles in peer-reviewed journals in March 2021.
Seven randomized controlled trials (RCTs) (total n = 260, active n = 148, control n = 112) and seven uncontrolled trials (total n = 160) were included. Overall, we found substantial variability in the clinical response, ranging from 6.7% to 54.3%.
The reviewed literature highlights large heterogeneity among studies both in terms of the employed TMS dosage and the observed clinical efficacy. This highlights the need for optimizing TMS dosage by recognizing the unique clinical features of GD. We showcase a set of novel approaches for the optimization of the TMS protocol for depression and discuss the possibility for a standardized TMS protocol tailored for the treatment of GD.
•TMS is a safe nonpharmacological intervention for geriatric depression.•TMS parameters adopted between different trials varied significantly.•TMS clinical efficacy for geriatric depression is highly variable between different trials.•Most of the reviewed studies significantly underdosed TMS for geriatric depression.•It is necessary to optimize TMS treatment by considering the changes of brain as we age.</description><subject>Aged</subject><subject>Aging</subject><subject>Depression - therapy</subject><subject>Geriatric depression (GD)</subject><subject>Humans</subject><subject>Non-invasive brain stimulation</subject><subject>Nonpharmacological intervention</subject><subject>Polypharmacy</subject><subject>Transcranial Magnetic Stimulation</subject><subject>Transcranial magnetic stimulation (TMS)</subject><subject>Treatment Outcome</subject><issn>1568-1637</issn><issn>1872-9649</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtOGzEUhi1E1VDoA7CpZgmLCb6Nx0eVUKuotEhULAhry-M5Th3NJbUnSLw9jhJQu2HjY-u_-Ogj5JzROaNMXa3nNsY5p5zt3pVgR-SE6ZqXoCQc53uldMmUqGfkU0prmjOg-EcyE1ILoFKckG_LaIfk8hFsV_R2NeAUXJGm0G87O4VxKC6Wvx8uCz_GYoUx2ClmvcVNxJSyfEY-eNsl_HyYp-Tx5sdy8au8u_95u_h-VzpZsalktPZCWs-9A6gBqasbVTEAy3TrJGjva8qBUqg0raXmbeVZ24C3jWiAM3FKrve9m23TY-twmKLtzCaG3sZnM9pg_leG8MesxiejAZTgkAsuDgVx_LvFNJk-JIddZwcct8lwRaWsVK1FtrK91cUxpYj-7RtGzY68WZtM3uzImz35nPny735viVfU2fB1b8BM6SlgNMkFHBy2IaKbTDuGd-pfABTDlDQ</recordid><startdate>20220201</startdate><enddate>20220201</enddate><creator>Cappon, Davide</creator><creator>den Boer, Tim</creator><creator>Jordan, Caleb</creator><creator>Yu, Wanting</creator><creator>Metzger, Eran</creator><creator>Pascual-Leone, Alvaro</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220201</creationdate><title>Transcranial magnetic stimulation (TMS) for geriatric depression</title><author>Cappon, Davide ; den Boer, Tim ; Jordan, Caleb ; Yu, Wanting ; Metzger, Eran ; Pascual-Leone, Alvaro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c451t-107f34af2fc9979e0c7b65199a18dc498ff70290095807482d5f1db9fab3b9213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Aged</topic><topic>Aging</topic><topic>Depression - therapy</topic><topic>Geriatric depression (GD)</topic><topic>Humans</topic><topic>Non-invasive brain stimulation</topic><topic>Nonpharmacological intervention</topic><topic>Polypharmacy</topic><topic>Transcranial Magnetic Stimulation</topic><topic>Transcranial magnetic stimulation (TMS)</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cappon, Davide</creatorcontrib><creatorcontrib>den Boer, Tim</creatorcontrib><creatorcontrib>Jordan, Caleb</creatorcontrib><creatorcontrib>Yu, Wanting</creatorcontrib><creatorcontrib>Metzger, Eran</creatorcontrib><creatorcontrib>Pascual-Leone, Alvaro</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Ageing research reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cappon, Davide</au><au>den Boer, Tim</au><au>Jordan, Caleb</au><au>Yu, Wanting</au><au>Metzger, Eran</au><au>Pascual-Leone, Alvaro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Transcranial magnetic stimulation (TMS) for geriatric depression</atitle><jtitle>Ageing research reviews</jtitle><addtitle>Ageing Res Rev</addtitle><date>2022-02-01</date><risdate>2022</risdate><volume>74</volume><spage>101531</spage><epage>101531</epage><pages>101531-101531</pages><artnum>101531</artnum><issn>1568-1637</issn><eissn>1872-9649</eissn><abstract>The prevalence of treatment-resistant geriatric depression (GD) highlights the need for treatments that preserve cognitive functions and recognize polypharmacy in elderly, yet effectively reduce symptom burden. Transcranial magnetic stimulation (TMS) is a proven intervention for treatment-resistant depression in younger adults but the efficacy of TMS to treat depressed older adults is still unclear. This review provides an updated view on the efficacy of TMS treatment for GD, discusses methodological differences between trials in TMS application, and explores avenues for optimization of TMS treatment in the context of the ageing brain.
A systematic review was conducted to identify published literature on the antidepressant efficacy of TMS for GD. Databases PubMed, Embase, and PsycINFO were searched for English language articles in peer-reviewed journals in March 2021.
Seven randomized controlled trials (RCTs) (total n = 260, active n = 148, control n = 112) and seven uncontrolled trials (total n = 160) were included. Overall, we found substantial variability in the clinical response, ranging from 6.7% to 54.3%.
The reviewed literature highlights large heterogeneity among studies both in terms of the employed TMS dosage and the observed clinical efficacy. This highlights the need for optimizing TMS dosage by recognizing the unique clinical features of GD. We showcase a set of novel approaches for the optimization of the TMS protocol for depression and discuss the possibility for a standardized TMS protocol tailored for the treatment of GD.
•TMS is a safe nonpharmacological intervention for geriatric depression.•TMS parameters adopted between different trials varied significantly.•TMS clinical efficacy for geriatric depression is highly variable between different trials.•Most of the reviewed studies significantly underdosed TMS for geriatric depression.•It is necessary to optimize TMS treatment by considering the changes of brain as we age.</abstract><cop>England</cop><pub>Elsevier B.V</pub><pmid>34839043</pmid><doi>10.1016/j.arr.2021.101531</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1568-1637 |
ispartof | Ageing research reviews, 2022-02, Vol.74, p.101531-101531, Article 101531 |
issn | 1568-1637 1872-9649 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8996329 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | Aged Aging Depression - therapy Geriatric depression (GD) Humans Non-invasive brain stimulation Nonpharmacological intervention Polypharmacy Transcranial Magnetic Stimulation Transcranial magnetic stimulation (TMS) Treatment Outcome |
title | Transcranial magnetic stimulation (TMS) for geriatric depression |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T13%3A27%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Transcranial%20magnetic%20stimulation%20(TMS)%20for%20geriatric%20depression&rft.jtitle=Ageing%20research%20reviews&rft.au=Cappon,%20Davide&rft.date=2022-02-01&rft.volume=74&rft.spage=101531&rft.epage=101531&rft.pages=101531-101531&rft.artnum=101531&rft.issn=1568-1637&rft.eissn=1872-9649&rft_id=info:doi/10.1016/j.arr.2021.101531&rft_dat=%3Cproquest_pubme%3E2604456783%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2604456783&rft_id=info:pmid/34839043&rft_els_id=S1568163721002786&rfr_iscdi=true |